AEON Biopharma, Inc. (AEON)
Total Valuation
AEON Biopharma has a market cap or net worth of $267.55 million. The enterprise value is $251.42 million.
| Market Cap | 267.55M |
| Enterprise Value | 251.42M |
Important Dates
The next estimated earnings date is Sunday, February 11, 2024, before market open.
| Earnings Date | Feb 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 37.16 million shares outstanding. The number of shares has decreased by -73.24% in one year.
| Shares Outstanding | 37.16M |
| Shares Change (YoY) | -73.24% |
| Shares Change (QoQ) | -73.24% |
| Owned by Insiders (%) | 41.89% |
| Owned by Institutions (%) | 22.80% |
| Float | 14.24M |
Valuation Ratios
The trailing PE ratio is 12.63.
| PE Ratio | 12.63 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19
| Current Ratio | 1.19 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.50% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.70M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -254,238 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.32% in the last 52 weeks. The beta is -0.03, so AEON Biopharma's price volatility has been lower than the market average.
| Beta (1Y) | -0.03 |
| 52-Week Price Change | -28.32% |
| 50-Day Moving Average | 5.43 |
| 200-Day Moving Average | 7.40 |
| Relative Strength Index (RSI) | 69.22 |
| Average Volume (30 Days) | 13,517 |
Short Selling Information
The latest short interest is 31,944, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 31,944 |
| Short Previous Month | 54,608 |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.22% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -45.70M |
| Pretax Income | -37.86M |
| Net Income | -37.60M |
| EBITDA | -37.83M |
| EBIT | -37.86M |
| Earnings Per Share (EPS) | $0.57 |
Balance Sheet
The company has $16.18 million in cash and $52,000 in debt, giving a net cash position of $16.13 million or $0.43 per share.
| Cash & Cash Equivalents | 16.18M |
| Total Debt | 52,000 |
| Net Cash | 16.13M |
| Net Cash Per Share | $0.43 |
| Equity / Book Value | -121.74M |
| Book Value Per Share | -3.28 |
| Working Capital | 2.73M |
Cash Flow
| Operating Cash Flow | -15.66M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.66M |
| FCF Per Share | -$0.42 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AEON Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -14.05% |
| FCF Yield | -5.85% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 73.24% |
| Shareholder Yield | 73.24% |
Analyst Forecast
The average price target for AEON Biopharma is $18.00, which is 150.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.00 |
| Price Target Difference | 150.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |